Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) insider Hendrik Scholl sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $165.99, for a total transaction of $331,980.00. Following the completion of the transaction, the insider owned 12,500 shares of the company’s stock, valued at approximately $2,074,875. The trade was a 13.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Hendrik Peter Scholl also recently made the following trade(s):
- On Thursday, October 1st, Hendrik Scholl sold 500 shares of Belite Bio stock. The shares were sold at an average price of $165.32, for a total transaction of $82,660.00.
Belite Bio Stock Down 1.1%
Shares of BLTE stock traded down $1.79 during trading hours on Monday, reaching $162.56. 191,275 shares of the stock traded hands, compared to its average volume of 173,816. The firm has a market capitalization of $6.55 billion, a PE ratio of -59.55 and a beta of -1.19. Belite Bio, Inc. Sponsored ADR has a 1-year low of $105.88 and a 1-year high of $200.00. The business has a fifty day moving average price of $160.26 and a 200 day moving average price of $160.22.
Belite Bio (NASDAQ:BLTE – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.19. Research analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.08 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
BLTE has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “hold” rating on shares of Belite Bio in a research report on Wednesday, September 9th. Zacks Research lowered Belite Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. UBS Group reissued a “buy” rating on shares of Belite Bio in a research note on Thursday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a research report on Friday, October 2nd. Finally, Canaccord Genuity Group lifted their target price on Belite Bio from $303.00 to $314.00 and gave the company a “buy” rating in a research note on Monday. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $226.91.
View Our Latest Research Report on Belite Bio
Institutional Investors Weigh In On Belite Bio
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLTE. Vise Technologies Inc. purchased a new position in shares of Belite Bio during the 3rd quarter valued at $217,000. GAMMA Investing LLC raised its holdings in shares of Belite Bio by 5.0% during the third quarter. GAMMA Investing LLC now owns 1,771 shares of the company’s stock worth $301,000 after acquiring an additional 85 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Belite Bio by 7.9% during the first quarter. Royal Bank of Canada now owns 2,257 shares of the company’s stock worth $360,000 after acquiring an additional 165 shares in the last quarter. Engineers Gate Manager LP boosted its position in Belite Bio by 11.4% during the second quarter. Engineers Gate Manager LP now owns 2,773 shares of the company’s stock valued at $427,000 after purchasing an additional 284 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Belite Bio by 104.0% during the first quarter. Bank of America Corp DE now owns 3,778 shares of the company’s stock valued at $602,000 after purchasing an additional 1,926 shares during the last quarter. Hedge funds and other institutional investors own 0.53% of the company’s stock.
Belite Bio Company Profile
Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.
Featured Stories
- Five stocks we like better than Belite Bio
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
